Literature DB >> 10984615

Cell-cycle regulation of the p53-inducible gene B99.

L Collavin1, M Monte, R Verardo, C Pfleger, C Schneider.   

Abstract

B99 is a p53-inducible gene whose accumulation upon p53 activation is restricted to late S/G2 cells. Here we have analyzed B99 regulation during the cell cycle in murine cells with or without functional p53. We report that B99 accumulates in late S/G2 phase, is phosphorylated in mitosis, and disappears in G1 phase, regardless of the status of p53. As a complement to this observation, we show that B99 is not induced by p53 in quiescent cells. Therefore, B99 expression is modulated both by cell-cycle regulatory mechanisms and by p53, and p53 can increase the cellular levels of B99 only during the window of the cell cycle when it is normally expressed. On the basis of these observations we rename B99 Gtse-1 (G-two- and S-phase-expressed).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10984615     DOI: 10.1016/s0014-5793(00)01969-4

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  13 in total

1.  Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway.

Authors:  Fei Chen; Zhuo Zhang; Jacquelyn Bower; Yongju Lu; Stephen S Leonard; Min Ding; Vince Castranova; Helen Piwnica-Worms; Xianglin Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-12       Impact factor: 11.205

2.  Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery.

Authors:  X Shawn Liu; Hongchang Li; Bing Song; Xiaoqi Liu
Journal:  EMBO Rep       Date:  2010-06-25       Impact factor: 8.807

3.  Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment.

Authors:  Débora Rosa Bublik; Massimiliano Scolz; Gianluca Triolo; Martín Monte; Claudio Schneider
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

4.  GTSE1 is a microtubule plus-end tracking protein that regulates EB1-dependent cell migration.

Authors:  Massimilano Scolz; Per O Widlund; Silvano Piazza; Debora Rosa Bublik; Simone Reber; Leticia Y Peche; Yari Ciani; Nina Hubner; Mayumi Isokane; Martin Monte; Jan Ellenberg; Anthony A Hyman; Claudio Schneider; Alexander W Bird
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

5.  p53 activates G₁ checkpoint following DNA damage by doxorubicin during transient mitotic arrest.

Authors:  Sun-Yi Hyun; Young-Joo Jang
Journal:  Oncotarget       Date:  2015-03-10

6.  GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells.

Authors:  Vinod Vijay Subhash; Shi Hui Tan; Woei Loon Tan; Mei Shi Yeo; Chen Xie; Foong Ying Wong; Zee Ying Kiat; Robert Lim; Wei Peng Yong
Journal:  BMC Cancer       Date:  2015-07-25       Impact factor: 4.430

7.  GTSE1 regulates spindle microtubule dynamics to control Aurora B kinase and Kif4A chromokinesin on chromosome arms.

Authors:  Aaron R Tipton; Jonathan D Wren; John R Daum; Joseph C Siefert; Gary J Gorbsky
Journal:  J Cell Biol       Date:  2017-08-18       Impact factor: 10.539

8.  GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis.

Authors:  Xiaojuan Wu; Hongbo Wang; Yifan Lian; Lubiao Chen; Lin Gu; Jialiang Wang; Yanlin Huang; Meihai Deng; Zhiliang Gao; Yuehua Huang
Journal:  Sci Rep       Date:  2017-07-11       Impact factor: 4.379

9.  High G2 and S-phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis.

Authors:  Tianxiao Xu; Meng Ma; Zhihong Chi; Lu Si; Xinan Sheng; Chuanliang Cui; Jie Dai; Sifan Yu; Junya Yan; Huan Yu; Xiaowen Wu; Huan Tang; Jiayi Yu; Yan Kong; Jun Guo
Journal:  Cancer Sci       Date:  2018-05-11       Impact factor: 6.716

10.  GTSE1: a novel TEAD4-E2F1 target gene involved in cell protrusions formation in triple-negative breast cancer cell models.

Authors:  Debora Stelitano; Leticia Yamila Peche; Emiliano Dalla; Martin Monte; Silvano Piazza; Claudio Schneider
Journal:  Oncotarget       Date:  2017-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.